Amphastar Pharmaceuticals, Inc. (AMPH) PT Raised to $17.00 at BMO Capital Markets

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) had its target price boosted by equities researchers at BMO Capital Markets from $16.00 to $17.00 in a note issued to investors on Friday. The brokerage currently has a “market perform” rating on the stock. BMO Capital Markets’ price target would indicate a potential downside of 8.36% from the company’s current price.

Several other brokerages also recently weighed in on AMPH. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Piper Jaffray Companies set a $19.00 target price on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, October 22nd. Wells Fargo & Company restated a “buy” rating on shares of Amphastar Pharmaceuticals in a research note on Saturday, July 22nd. Jefferies Group LLC set a $19.00 price objective on shares of Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, October 29th. Finally, Raymond James Financial, Inc. downgraded shares of Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 price objective for the company. in a research note on Thursday. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $20.43.

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) traded down $0.26 on Friday, reaching $18.55. 305,700 shares of the company’s stock traded hands, compared to its average volume of 194,598. The firm has a market capitalization of $852.85, a P/E ratio of 123.67, a price-to-earnings-growth ratio of 8.24 and a beta of 1.68. Amphastar Pharmaceuticals has a 52 week low of $12.05 and a 52 week high of $21.75. The company has a current ratio of 3.04, a quick ratio of 1.87 and a debt-to-equity ratio of 0.12.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.05. The company had revenue of $57.90 million during the quarter, compared to the consensus estimate of $57.23 million. Amphastar Pharmaceuticals had a net margin of 0.12% and a return on equity of 2.30%. Amphastar Pharmaceuticals’s revenue was down 9.8% compared to the same quarter last year. During the same period last year, the firm earned $0.14 earnings per share. research analysts anticipate that Amphastar Pharmaceuticals will post 0.09 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals announced that its board has approved a stock buyback program on Wednesday, August 9th that authorizes the company to buyback $20.00 million in shares. This buyback authorization authorizes the company to purchase up to 2.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.themarketsdaily.com/2017/11/13/amphastar-pharmaceuticals-inc-amph-pt-raised-to-17-00-at-bmo-capital-markets.html.

In other news, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $14.81, for a total transaction of $148,100.00. Following the completion of the sale, the director now directly owns 33,844 shares in the company, valued at $501,229.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael A. Zasloff sold 63,624 shares of Amphastar Pharmaceuticals stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $18.18, for a total transaction of $1,156,684.32. Following the sale, the director now owns 101,879 shares of the company’s stock, valued at $1,852,160.22. The disclosure for this sale can be found here. Insiders have sold 170,285 shares of company stock valued at $3,079,995 over the last quarter. Insiders own 11.10% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Nationwide Fund Advisors lifted its position in Amphastar Pharmaceuticals by 11.9% during the second quarter. Nationwide Fund Advisors now owns 49,266 shares of the company’s stock valued at $880,000 after purchasing an additional 5,233 shares during the period. OppenheimerFunds Inc. acquired a new position in Amphastar Pharmaceuticals during the first quarter valued at $215,000. Schwab Charles Investment Management Inc. lifted its position in Amphastar Pharmaceuticals by 7.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 218,080 shares of the company’s stock valued at $3,895,000 after purchasing an additional 14,646 shares during the period. Argent Capital Management LLC acquired a new position in Amphastar Pharmaceuticals during the second quarter valued at $1,069,000. Finally, Dimensional Fund Advisors LP lifted its position in Amphastar Pharmaceuticals by 32.5% during the first quarter. Dimensional Fund Advisors LP now owns 1,061,188 shares of the company’s stock valued at $15,388,000 after purchasing an additional 260,288 shares during the period. Institutional investors own 43.98% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply